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ABSTRACT
The effects of a 12- to 24-month treatment with depot long-acting
octreotide (OCT-LAR) on hormone profile, tumor mass, and clinical
symptoms were reported in 36 patients with active acromegaly [GH,
34.2 6 5.6 mg/L; insulin-like growth factor I (IGF-I), 784.5 6 40.4
mg/L]. Fifteen patients were de novo whereas 21 had previously un-
dergone unsuccessful surgery.
Serum GH (P , 0.0001) and IGF-I levels (P , 0.0001) significantly
decreased as early as after the first injection of OCT-LAR and pro-
gressively declined during the 12–24 months of treatment both in de
novo and in operated patients. At the last follow-up, GH hypersecre-
tion was controlled (#2.5 mg/L) in 69.4% whereas normal IGF-I levels
were achieved in 61.1% of patients. GH and IGF-I suppression during
OCT-LAR treatment was similar in de novo and operated patients as
shown by nadir GH (2.3 6 0.6 vs. 2.2 6 0.6 mg/L) and IGF-I (323.1 6
34.9 vs. 275.5 6 33.0 mg/L), percent suppression of GH (92.7 6 2.0 vs.
85.9 6 3.3%) and IGF-I (57.4 6 4.9 vs. 61.5 6 4.6%), and prevalence
of GH (73.3 vs. 76.2%) and IGF-I (53.3 vs. 71.4%) control. A decrease
in tumor volume was observed in 12 of 15 de novo patients, whereas
no shrinkage was detected in 4 of 9 operated patients. No patient had
tumor reexpansion during OCT-LAR treatment. Significant clinical
improvement was obtained in all patients; heart rate, systolic blood
pressure, and diastolic blood pressure significantly decreased in the
entire population. A mild but significant increase of blood glucose
levels, followed by a decrease of serum insulin levels, was observed
after 3 months of treatment: this effect subsided with treatment
continuation. OCT-LAR treatment was well tolerated by most
patients.
In conclusion, long-term treatment with OCT-LAR was effective in
controlling GH and IGF-I hypersecretion in most patients with ac-
romegaly, when applied either as primary therapy or as adjunctive
therapy after surgery. Tumor shrinkage was observed in de novo
patients during OCT-LAR treatment, suggesting that it can be suc-
cessfully applied as primary therapy in patients bearing invasive
tumors, who are less likely to be cured after surgery. (J Clin Endo-
crinol Metab 86: 2779–2786, 2001)
PHARMACOTHERAPY WITH SOMATOSTATIN ana-logs is currently regarded as a potential option for the
primary therapy of acromegaly. In fact, sc octreotide (OCT)
administration in de novo acromegalic patients induced sup-
pression of GH and insulin-like growth factor I (IGF-I) levels
that was similar to that observed in patients who received
OCT treatment after surgery (1). This finding has opened the
question of the best treatment strategy in acromegaly. The
availability of the slow-release formulation of OCT (OCT-
LAR) has further improved the medical approach to this
systemic disease. OCT-LAR was developed to enable once-
monthly administration, producing stable blood concentra-
tions of the drug, resulting in sustained GH and IGF-I sup-
pression (2). In a dose-ranging study, OCT-LAR was shown
to suppress GH and IGF-I levels to a similar extent as the sc
formulation in 21 acromegalic patients (3). In a multicenter
study, OCT-LAR administered im at 4-week intervals to 151
patients responsive to sc OCT, induced control of GH (#2.5
mg/L) and IGF-I secretion in 69.8% and 65.8% vs. 65.8% and
63.1% during prior treatment with sc OCT, respectively (4).
Similar data have been reported in small series of patients
treated for 12–36 months (5–8). Systemic and local tolera-
bility as well as patients’ compliance were reported to be very
good (4–8).
Because data concerning the long-term efficacy of this
drug, mostly on tumor mass, are still scant, we investigated
the effects of a 12- to 24-month OCT-LAR treatment on hor-
mone profile, tumor mass, and clinical symptoms in 36 ac-
romegalic patients. The potential difference in applying
OCT-LAR treatment as primary therapy or after surgery was
also investigated.
Patients and Methods
Patients
Thirty-six patients with active acromegaly (21 women and 15 men;
age range, 24–77 yr; median, 56 yr) and never treated before with
somatostatin analogs, except for a short (#3 months) treatment before
surgery, were enrolled into the study after their informed consent had
been obtained. Twenty-one patients had previously undergone unsuc-
cessful surgery. The laboratory diagnosis of acromegaly was defined by
high serum GH levels (34.2 6 5.6 mg/L; mean 6 sem) during a 6-h time
course, not suppressible below 2 mg/L after a 75-g oral glucose tolerance
test (oGTT) and high plasma IGF-I levels for age (784.5 6 40.4 mg/L) (9).
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Two patients suffered from overt diabetes mellitus and did not receive
oGTT. The presumed duration of acromegaly was assessed by compar-
ison of patients’ photographs taken during a one- to three-decade span
and by interviews to estimate the date the onset of acral enlargement.
In this series, disease duration ranged between 5 and 35 yr (16.9 6 1.4
yr). The patients’ profile at study entry is shown in Table 1. To improve
the clinical conditions (10), 16 of the 21 patients operated on had received
somatostatin analog treatment with sc OCT at a dose of 0.1 mg three
times a day (5 patients), lanreotide at a dose of 30 mg every 14 days (8
patients), and OCT-LAR at a dose of 20 mg every 28 days (3 patients):
in these patients the assessment of disease activity was performed at
least 3 months after surgery. The only exclusion criteria for de novo
patients was the presence of visual field defects or other neurological
symptoms due to tumor mass.
Study protocol
At study entry plasma IGF-I levels were assayed twice in a single
sample, whereas the value of serum GH was calculated as the mean of
a 6-h blood sampling (0800–1400 h with 30-min sampling). During
treatment, the final GH level was calculated as the average value from
at least three blood samples collected, at 15-min intervals, the morning
before the next injection of OCT-LAR. At this time point, plasma IGF-I
concentrations were assayed as single sampling. Hormonal and clinical
evaluations were carried out before, monthly for the first 3 months, and
quarterly during the treatment. Hormone normalization after OCT-LAR
treatment was considered when basal GH values were 2.5 mg/L or lower
as fasting sample or 1 mg/L or lower after glucose load, together with
IGF-I values within the normal range for age (11, 12). Blood pressure was
measured at study entry and quarterly during OCT-LAR treatment in
the right arm, with the subjects in a relaxed sitting position. Before and
after 12 and 24 months of treatment, the average of six measurements
(three taken by each of two examiners) with a mercury sphygmoma-
nometer was taken. Hypertension was diagnosed when diastolic blood
pressure (DBP) values were more than 90 mm Hg and was graded as
mild when between 91 and 104 mm Hg, moderate when 105–114 mm Hg,
and severe when more than 115 mm Hg, in line with WHO criteria (13).
Among the 36 patients, 13 (36.1%) had mild hypertension. Fasting glu-
cose, triglycerides, and total cholesterol levels were measured by stan-
dard procedures. At study entry impaired glucose tolerance was diag-
nosed after oGTT (75 g glucose diluted in 250 mL saline solution,
measuring blood glucose every 30 min for 2 h). Diabetes mellitus was
diagnosed when fasting glucose was above 7 mmol/L at two consec-
utive measurements or when 2 h after the oGTT, glucose was 11.1
mmol/L or higher (14). Impaired glucose tolerance was diagnosed when
glucose was between 7 and 11.1 mmol/L 2 h after the oGTT with an
additional value 11.1 mmol/L or lower between 0 and 2 h after the oGTT
(14). Among the 36 patients, 2 (5.5%) had diabetes mellitus and 6 (16.7%)
had glucose intolerance. Fasting insulin levels were also measured in all
patients. In all patients gallbladder and biliary system ultrasonography
was performed before and every 6 months during OCT-LAR treatment.
Treatment protocol
All patients, but the 16 who were treated with somatostatin analogs
before surgery, received an acute test with sc OCT at a dose of 0.1 mg
to investigate individual patient tolerability to somatostatin analogs (15).
In all patients OCT-LAR was initially administered im at a dose of 20
mg every 28 days for 3 months. Then, the dose of OCT-LAR was in-
creased to 30 mg every 28 days on the basis of GH levels above 5 mg/L
in 15 patients (16). After 12 months of treatment the dose of OCT-LAR
was further increased to 40 mg every 28 days in seven patients (1, 2, 18,
20, 21, 27, and 29; Table 1) and was decreased to 10 mg every 28 days
in two elderly patients (14 and 15; Table 1) who achieved fasting GH
levels below 1 mg/L. At the end of the study, the dose of OCT-LAR was
10 mg in 2 patients (5%), 20 mg in 14 patients (38.9%), 30 mg in 11 patients
(30.5%), and 40 mg in 8 patients (22.2%) (Table 1). One man died of a
heart attack 2 months after beginning therapy, and two women died
during the follow-up: the former after 48 months of treatment for uterus
carcinoma at the age of 58 yr, and the latter after 30 months of treatment
for cachexia due to the nutritional problems caused by hesofageal aca-
lasia at the age of 81 yr. Thirty-five patients completed the 12-month
follow-up, 32 patients completed the 18-month follow-up, and 28 pa-
tients completed the 24-month follow-up (Table 1).
Assays
Serum GH levels were measured by immunoradiometric assay
(IRMA) (HGH-CTK-IRMA; Sorin, Saluggia, Italy). The sensitivity of the
assay was 0.2 mg/L; 1 mg/L corresponds to 2.5 mU/L. The intra- and
interassay coefficients of variation (CV) were 4.5% and 7.9%, respec-
tively. Plasma IGF-I was measured by IRMA after ethanol extraction
using DSL kits (Diagnostic Systems Laboratories, Inc., Webster, TX). The
sensitivity of the assay was 0.8 mg/L. The intra-assay CV were 3.4%,
3.0%, and 1.5% for the low, medium, and high points on the standard
curve, respectively. The interassay CV were 8.2%, 1.5%, and 3.7% for the
low, medium, and high points on the standard curve. Fasting GH levels
were considered above the normal range when higher than 2.5 mg/L. In
our laboratories the normal IGF-I range in 20–30, 31–40, 41–50, and over
50-yr-old subjects was 110–502, 100–494, 100–303, and 78–258 mg/L,
respectively.
Magnetic resonance imaging (MRI) studies
MRI studies were performed on clinical 0.5T and 1T scanners, using
T1-weighted gradient recalled-echo (repetition time, 200–300 millisec-
onds; echo time, 10–12 milliseconds; flip angle, 90 degree, four signal
averages) in the sagittal and coronal planes. In each measurement 7–11
slices were obtained, with a slice thickness of 2–3 mm and an in-plane
spatial resolution of 0.7–0.97 mm (the matrix was 192–256 3 256 on a
field of view of 24–25 cm on the sagittal plane and 160–256 3 256 on a
field of view of 18–20 cm in the coronal plane). The acquisitions were
repeated before and after the administration of 0.1 mmol gadolinium
chelate (diethylene-triamine pentacetate). MRI was performed before
and after 3, 6, 12, and 24 months of OCT-LAR treatment in de novo
patients and before and after 12 and 24 months in operated patients. In
de novo patients shrinkage was established on tumor volume calculated
by the Di Chiro and Nelson formula: volume 5 height 3 length 3
width 3 p/6 (17) and on the maximal tumor diameter, whereas in
patients previously operated on shrinkage was established only on the
maximal tumor diameter. Tumor shrinkage was evaluated as a reduc-
tion of the pretreatment tumor volume or maximal tumor diameter,
respectively, in a semiquantitative way as: less than 25% or less than
10%, no shrinkage; 26–50% or 11–20%, mild shrinkage; 51–75% or 21–
30%, moderate shrinkage; more than 75% or more than 30%, notable
shrinkage. The radiologist (S.C.) was blind in respect to the status of the
patient.
Visual perimetry
In all patients the assessment of visual field defects, by Goldmann-
Friedmann perimetry, and visual acuity was performed at baseline. The
ophthalmologic examination was repeated every 6 months during the
follow-up in the patients with visual disturbances.
Statistical analysis
The statistical analysis was performed by means of an SPSS, Inc.
(Cary, NC) package. The effect of OCT-LAR was analyzed by the paired
Student’s t test, ANOVA, x2 test, and linear regression analysis,
where appropriate. Data are reported as mean 6 sem.
Results
Effect of long-term OCT-LAR treatment on GH and
IGF-I levels
A significant decrease of circulating GH (from 34.2 6 5.6
to 12.5 6 2.5 mg/L, P , 0.0001) and IGF-I levels (from 784.5 6
40.4 to 582.2 6 42.1 mg/L, P , 0.0001) was observed early
after the first injection of OCT-LAR. At this time point, GH
and IGF-I decrease was similar in the 16 patients who re-
ceived the short presurgical treatment with somatostatin an-
alogs and the remaining patients (data not shown). Serum
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GH (3.5 6 0.7 mg/L, P , 0.0001) and IGF-I levels (335 6 26.2
mg/L, P , 0.0001) progressively declined during the first 12
months of treatment both in de novo (Fig. 1) and in operated
patients (Fig. 2). After 12 months of treatment with OCT-
LAR, the percent GH and IGF-I suppression was 83.8 6 3.2%
and 55.2 6 3.3%, respectively. In the 28 patients treated for
24 months serum GH (from 3.5 6 0.8 to 2.4 6 0.5 mg/L, P 5
0.04) and IGF-I levels (from 333.2 6 31.2 to 290.1 6 30.0 mg/L,
P 5 0.001) were further decreased compared with the 12-
month follow-up. After 1, 3, 6, 12, 18, and 24 months of
OCT-LAR treatment, in the whole population GH hyperse-
cretion was controlled (#2.5 mg/L) in 16.7%, 34.3%, 60%,
68.6%, 71.8%, and 71.4%, whereas normal IGF-I levels were
achieved in 20%, 20%, 42.8%, 48.6%, 56.3%, and 67.8%, re-
spectively. At the last follow-up GH levels were 1 mg/L or
lower in 15 patients (41.7%), 1.1–2.5 mg/L in 11 patients
(30.6%), 2.6–5 mg/L in 5 patients (14.3%), and higher than 5
mg/L in 5 patients.
At study entry, the 15 de novo patients had similar age
(50.5 6 3.8 vs. 54.3 6 2.8 yr) and IGF-I levels (861.3 6 75.2 vs.
729.5 6 41.4 mg/L) but higher GH levels (55.1 6 10.8 vs.
19.5 6 3 mg/L, P , 0.001) than the 21 patients treated with
OCT-LAR after surgery. However, no difference was found
in GH and IGF-I suppression during OCT-LAR treatment
between de novo and operated patients. In fact, nadir GH
(2.3 6 0.6 vs. 2.2 6 0.6 mg/L) and IGF-I (323.1 6 34.9 vs.
275.5 6 33.0 mg/L) and the percent GH (92.7 6 2.1 vs.
85.963.3%) and IGF-I suppression (57.4 6 4.9 vs. 61.564.6%)
achieved after long-term treatment with OCT-LAR were sim-
ilar in de novo and operated patients as was the prevalence
of GH (73.3 vs. 76.2%) and IGF-I (53.3 vs. 71.4%) control. In
20 patients GH nadir after acute OCT test was available: as
expected, nadir GH after acute octreotide administration was
higher than during chronic treatment (5.7 6 1.3 vs. 2.4 6 0.4
mg/L, P 5 0.007); nadir GH after acute and chronic treatment
were significantly correlated each other (r2 5 0.32; P 5
0.0007).
Effect of 12–24 months of OCT-LAR treatment on tumor
shrinkage
A remarkable decrease in tumor volume was observed in
de novo patients during OCT-LAR treatment (Fig. 3). After 3
months only five patients had a mild-to-moderate shrinkage.
FIG. 1. Individual serum GH (top) and IGF-I (bottom) levels before
and during OCT-LAR treatment in de novo patients. The interrupted
line indicates the threshold of 2.5 mg/L, which is considered the nor-
mal limit for GH levels.
FIG. 2. Individual serum GH (top) and IGF-I (bottom) levels before
and during OCT-LAR treatment in patients subjected to surgery
before starting OCT-LAR treatment. The interrupted line indicates
the threshold of 2.5 mg/,L which is considered the normal limit for GH
levels.
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In contrast, at the last follow-up shrinkage was absent in
three patients (20%), mild in three (20%), moderate in six
(40%), and notable in three patients. Two patients with mi-
croadenoma had disappearance of their tumors after 6–12
months of treatment. In one patient with microadenoma a
remarkable tumor decrease was observed after 3 months of
OCT-LAR treatment at a dose of 20 mg every 28 days (Fig.
4). Tumor shrinkage was evaluated in only 9 of the 21 op-
erated patients (Table 1): shrinkage was absent in 4, mild in
1, moderate in 3, and notable in 1 patient. After 12 and 24
months of treatment, no difference was found in the maximal
tumor diameter both in the eight de novo (11.1 6 2.7 vs. 10.3 6
2.5 mm) and in the nine operated patients (10.7 6 2.2 vs.
10.2 6 2.2 mm). At the last follow-up, the decrease in the
maximal tumor diameter was slightly but not significantly
higher in de novo (31.1 6 7.6%) than in operated patients
(14.8 6 4.4%). In de novo patients, no correlation was found
between tumor volume and age, disease duration and base-
line GH and IGF-I levels, or between the percent tumor
reduction and percent GH/IGF-I suppression or the dose of
OCT-LAR. No patient had tumor reexpansion during OCT-
LAR treatment. No de novo patient had visual field defects at
study entry whereas 4 of the 21 operated patients had tem-
poral quadrantopsia that did not significantly improve dur-
ing OCT-LAR treatment.
Effect of 12–24 months of OCT-LAR treatment on clinical
symptoms and biochemical data
All patients obtained significant clinical improvement
during OCT-LAR treatment: specifically, patients reported
improvement of headache (n 5 10), hyperhidrosis (n 5 15),
asthenia (n 5 5), and osteo-articular pain and mobility (n 5
22). Reduction of soft tissue swelling was noted by all pa-
tients. In addition, during treatment, heart rate [from 92.1 6
1.6 to 86.0 6 1.2 beats per minute (bpm) after 12 months and
83.9 6 1.6 bpm after 24 months, P , 0.01], systolic blood
pressure (from 138.6 6 1.5 to 134.4 6 1.2 mm Hg after 12
months and 132.4 6 1.5 mm Hg after 24 months, P , 0.01),
and DBP (from 88.9 6 1.1 to 86.3 6 0.9 bpm after 12 months
and 84.9 6 1.0 bpm after 24 months, P , 0.05) significantly
decreased in the population as a whole. Among the 13 pa-
tients with mild hypertension, only 3 still had DBP above 90
mm Hg and remained under specific antihypertensive treat-
ment. The patient who died of a heart attack had mild hy-
pertension and was specifically treated at study entry. No
difference was observed in the clinical improvement be-
tween de novo and operated patients. Similarly, with the
exclusion of the two diabetic patients, no difference was
found in blood glucose, triglycerides, and total cholesterol
levels before and after 12–24 months of treatment, although
a mild but significant increase of blood glucose levels (5.3 6
0.3 vs. 5.9 6 0.2 mmol, P , 0.05) followed by a decrease of
serum insulin levels (17.7 6 3.4 vs. 10.5 6 3.1 mU/L, P , 0.05)
was observed after 3 months of treatment. However, at the
end of OCT-LAR treatment blood glucose (5.5 6 0.3
mmol/L) and insulin (15.0 6 3.2 mU/L) were similar to
pretreatment values. Both diabetic patients reduced insulin
requirements during OCT-LAR treatment, and one of the six
patients with impaired glucose tolerance required additional
treatment with glucose-lowering drugs.
Tolerability
OCT-LAR treatment was well tolerated by most patients:
abdominal discomfort was reported by 10 (27.8%), steator-
rhea by 4 (11.1%), flatulence by 10, and hair loss by 4 patients.
These side effects spontaneously disappeared in seven cases
and after treatment with pancreatic enzymes in the others.
Hair loss stopped after 3–6 months. Asymptomatic gall-
stones were detected in two patients whereas in another
patient colecystectomy for acute colecystitis was performed
after 12 months of treatment. This latter patient was with-
drawn from OCT-LAR treatment.
Discussion
Acromegaly is a chronic and slowly developing disease
that causes progressive disability and shortens life (18, 19).
Its optimal treatment is the selective removal of the GH-
secreting pituitary adenoma, which should, consequently,
result in the normalization of GH and IGF-I secretion, with-
out causing secondary hypopituitarism and with minimal
side effects and morbidity. Trans-sphenoidal surgery seems
to be the most appropriate therapeutic measure and is as-
sociated with very low morbidity and a low recurrence rate
(20–22). However, the results of surgery reported from many
centers over the last 20 yr are difficult to compare with our
practice because the criteria used to define the control of
acromegaly have changed (12) and the success of surgery has
improved with the increasing experience of pituitary sur-
geons and the improvement in surgical technique (23). How-
ever, in one recent series of 115 patients undergoing trans-
sphenoidal surgery (20), remission after surgery alone was
achieved in 61%, but in only 53% of patients with macroad-
enoma. A similar result was reported by Swearingen et al.
(21). Therefore, it is presently accepted that disease control
after surgery alone can be achieved in a high proportion of
cases with relatively small enclosed adenomas (11, 24, 25). In
patients with invasive adenomas it is, therefore, necessary to
use pharmacotherapy to achieve disease control (11, 24, 25).
The treatment with somatostatin analogs, particularly OCT
(26), has been widely shown to rapidly and effectively reduce
GH hypersecretion and to decrease IGF-I concentrations. On
FIG. 3. Individual values of tumor volume before and during OCT-
LAR treatment in de novo acromegalic patients, shown in order of age
as in Table 1.
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the other hand, a recent multicenter study has demonstrated
that no difference existed in the GH and IGF-I suppression
after sc OCT treatment between patients treated with this
drug primarily and those treated after unsuccessful surgery
(1). This relevant result has opened the question as to
whether surgery should still be considered as primary ther-
apy of all patients with acromegaly. The recent availability
of somatostatin analogs provided in slow-release formula-
tions such as lanreotide (27–30), and OCT-LAR (4–8) has
further improved patients’ compliance to long-term treatment.
In accord with previous studies (4–7), the results of the
present study show that treatment with OCT-LAR is highly
effective in controlling GH and IGF-I hypersecretion in the
majority of acromegalic patients (71.4% and 67.8%, respec-
tively). In particular, a significant decrease of GH and IGF-I
levels was noted after the first injection of 20 mg OCT-LAR.
Interestingly, although de novo patients presented with
higher GH levels at study entry than operated patients, the
final therapeutic effect of OCT-LAR was identical in these
two subgroups of acromegalics. These results confirmed
FIG. 4. Coronal (left) and sagittal (right) sections of a pituitary microadenoma in patient 5 before (top) and after (bottom) 3 months of OCT-LAR
at a dose of 20 mg every 28 days.
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those reported by Newman et al. (1) in a multicenter trial
involving a large cohort of patients treated with sc OCT.
Following the decrease of GH and IGF-I levels, significant
improvement of clinical symptoms was experienced by the
majority of our patients: in particular, they reported im-
provement in the articular mobility at the hands and knees,
and 10 of 11 patients had dramatic improvement of head-
ache. Besides these effects, we observed an early impairment
of glucose tolerance that was, however, short-lasting and an
overall improvement of blood pressure during OCT-LAR
treatment. A clinically insignificant reduction of heart rate
was also noted, confirming previous results obtained with sc
OCT (31).
One of the most relevant results of this study is that 53.3%
of patients treated with OCT-LAR as primary therapy had a
moderate-to-notable decrease of tumor volume with an av-
erage value of 53.1 6 6.7% tumor reduction after 12 months
of treatment, leading to tumor disappearance in two patients
bearing microadenoma at study entry. In de novo patients, the
shrinking effect of OCT-LAR was progressive during long-
term treatment although the most dramatic tumor reduction
was observed at the 3-month follow-up (29.8 6 5.1 after 3
months vs. 7.9 6 3%, 18.8 6 4.2% and 5.4 6 3.1% after 6, 12,
and 24 months, respectively). The effect on tumor size of
OCT-LAR has already been reported to occur in 29–72% of
patients (8): however, the majority of these patients had
already been treated by surgery and/or radiotherapy. The
degree of tumor reduction varied from 20% (3, 32) to 100%
(5) and was reported both in micro- and in macroadenomas
(8). These results are in line with those observed in our
patients. However, in the present study the reduction in the
maximal tumor diameter was slightly lower in operated than
in de novo patients (14.8 6 4.4 vs. 31.1 6 7.6%). Whether
surgical manipulation of the tumor, causing fibrosis and
histological changes in tumor tissue, can be considered re-
sponsible for the scant shrinking effect of OCT-LAR therapy
in remnant tumors or whether the irregularity of the mor-
phology of remnant tumors does not allow a precise esti-
mation by MRI of remnant size cannot be ruled out. A similar
result was, however, recorded in another large series of pa-
tients treated with lanreotide, another slow-release formu-
lation (33).
The incidence of side effects was scant, and patients’ com-
pliance to the long-term treatment was excellent. These re-
sults are in agreement with previous studies of shorter du-
ration (4–7). However, one patient was withdrawn from
OCT-LAR because of acute colecystitis treated by
colecystectomy.
In conclusion, long-term treatment with OCT-LAR was
effective in normalizing GH and IGF-I levels in as many as
69.2% and 73.7% of patients with acromegaly, respectively,
without any difference when applied as either primary ther-
apy or as adjunctive therapy after surgery. The incidence of
side effects during treatment was scant, even in patients
treated with 40 mg every 28 days. Interestingly, notable
tumor shrinkage was observed in de novo patients during
OCT-LAR treatment, most evident as early as after 3 months.
On this basis, OCT-LAR can be considered as a very effective
and well tolerated treatment for acromegaly and can be suc-
cessfully applied as primary therapy in patients bearing in-
vasive tumors, who are less likely to be cured after surgery.
In fact, even considering that the cost of the medical treat-
ment is currently rather elevated, in these patients the global
cost of the treatment includes that of the unsuccessful sur-
gery and of the medication.
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